The purpose of this study is to evaluate the efficacy and safety of favipiravir combined with tocilizumab in the treatment of corona virus disease 2019.
In clinical institutions that enroll patients with corona virus disease 2019, three arms,
multi-center, randomized and controlled methods are adopted. Patients are divided into three
groups, favipiravir combined with tocilizumab group, favipiravir group and tocilizumab group.
150 patients are expected to be enrolled and the cases are allocated according to the ratio
of 3( favipiravir combined with tocilizumab group): 1(favipiravir group): 1(tocilizumab
group).
Drug: Favipiravir Combined With Tocilizumab
Favipiravir: On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.
Tocilizumab:The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.
Drug: Favipiravir
On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.
Drug: Tocilizumab
The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.
Inclusion Criteria:
1. Clinically diagnosed with Corona Virus Disease 2019
2. Increased interleukin-6
3. Sign the informed consent
4. Subjects who can take medicine orally
5. Agree to collect clinical samples
6. Female subjects of childbearing age are not pregnant and agree to take effective
contraception within 7 days of the last oral medication to ensure that they are not
pregnant within 3-6 months
7. Male patients agree to effective contraception within 7 days of last oral medication.
Exclusion Criteria:
1. Cases of severe vomiting that make it difficult to take the drug orally
2. Allergic to Favipiravir or tocilizumab
3. Pregnant and lactating women
4. Subjects received specific antiviral drugs such as lopinavir / ritonavir, ribavirin,
arbidol, chloroquine phosphate, hydroxychloroquine, and monoclonal antibodies within
one week before admission.
5. Cases of respiratory failure and requiring mechanical ventilation
6. Cases of shock
7. Combined organ failure requires ICU monitoring and treatment
8. Predicted clinically that there is no hope of survival, or cases of deep coma that do
not respond to supportive treatment measures within three hours of admission
9. Alanine aminotransferase / Aspartate aminotransferase> 5 times of upper limit of
normal
10. Neutrophils <0.5 × 10^9 / L, platelets less than 50 × 10^9 / L
11. Clear diagnosis of rheumatoid immunity, malignant tumors and other related diseases
12. Long-term oral anti-rejection drugs or immunomodulatory drugs
13. Allergic reactions to tocilizumab or any excipients
14. Patients with active hepatitis, tuberculosis, and definite bacterial and fungal
infections
15. Organ transplant patients
16. Patients with mental disorders
Guiqiang Wang
Beijing, Beijing, China
Peking University First Hospital
Beijing, Beijing, China
Ezhou Central Hospital
Wuhan, Hubei, China
Huoshenshan Hospital of Wuhan
Wuhan, Hubei, China
Jinyintan Hospital of Wuhan
Wuhan, Hubei, China
Wuhan Pulmonary Hospital
Wuhan, Hubei, China
Guiqiang Wang
13911405123
john131212@sina.com
Hong Zhao
13810765943
zhaohong_pufh@bjmu.edu.cn
Guiqiang Wang, Principal Investigator
Peking University First Hospital